利那洛肽减轻IBS-C腹胀、不适与疼痛:3B期多条目腹部评分试验
这项3B期随机对照试验纳入614例便秘型肠易激综合征(IBS-C)患者,评估利那洛肽290 μg每日一次对比安慰剂12周的疗效。主要终点为新型多条目腹部评分(AS)的总体变化,利那洛肽组降幅-1.9优于安慰剂组-1.2(P<0.0001),6周/12周AS应答率40.5%对23.4%(OR=2.2,95%CI 1.55-3.12,P<0.0001),所有预设终点均显著获益。
要点
- 利那洛肽290 μg每日一次治疗12周,IBS-C患者腹部症状综合评分显著优于安慰剂。
- AS应答率(改善≥2分)利那洛肽组40.5%,安慰剂组23.4%,OR=2.2(95%CI 1.55-3.12)。
- 腹泻为最常见治疗中出现的不良事件,利那洛肽组4.6%,安慰剂组1.6%。
核心结论
- 利那洛肽可显著改善IBS-C患者腹胀、不适与疼痛等多维腹部症状,优于安慰剂。
研究设计与样本
- 3B期随机对照试验,614例IBS-C患者(基线腹痛≥3分,0-10量表)随机接受利那洛肽290 μg或安慰剂每日一次,治疗12周。
- 主要终点为新型多条目腹部评分(AS)相对基线的总体变化,AS取腹胀、不适、疼痛最严重程度的均值(0=无,10=最严重)。
主要发现
- AS总体平均变化:利那洛肽组-1.9,安慰剂组-1.2(P<0.0001)。
- 6周/12周AS应答率(改善≥2分):利那洛肽组40.5%,安慰剂组23.4%(OR=2.2,95%CI 1.55-3.12,P<0.0001)。
- 腹泻为最常见治疗中出现的不良事件:利那洛肽组4.6%,安慰剂组1.6%。
关键数值与推荐
- AS为腹胀、不适、疼痛最严重程度的均值,0=无,10=最严重。
- AS应答定义为AS改善≥2分且持续≥6周/12周。
临床怎么用
- 对IBS-C患者使用利那洛肽290 μg每日一次,可同步改善腹胀、不适与疼痛等腹部症状。
- 临床评估可参考多条目AS评分体系,关注腹部症状综合改善而非仅传统终点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Linaclotide improves abdominal pain and constipation in patients with constipation-predominant irritable bowel syndrome (IBS-C). Patients report additional bothersome abdominal symptoms of bloating and discomfort. The intention of this study was to evaluate linaclotide's efficacy in relieving IBS-C-related abdominal symptoms (bloating, discomfort, and pain) using a novel multi-item Abdominal Score (AS). METHODS: Patients with IBS-C with abdominal pain ≥3 (0-10 scale) were randomized to linaclotide 290 μg or placebo daily for 12 weeks. The AS, derived from the Diary for IBS Symptoms-Constipation, is the average of abdominal bloating, discomfort, and pain at their worst (0 = none, 10 = worst possible). The primary end point was overall change from baseline (CFB) in AS. Secondary end points included CFB in 12-week AS evaluated using cumulative distribution function and 6-week/12-week AS responder (AS improvement ≥2 points for ≥6-week/12-week). RESULTS: Overall, 614 patients (mean age 46.7 years; 81% female) were randomized. All prespecified end points showed significant benefit of linaclotide vs placebo. The mean overall CFB AS reduction for linaclotide was -1.9 vs -1.2 for placebo (P < 0.0001); the 6-week/12-week AS responder rate was 40.5% for linaclotide vs 23.4% for placebo (odds ratio = 2.2 [95% confidence interval, 1.55-3.12; P < 0.0001]). Diarrhea was the most common treatment-emergent adverse event (linaclotide = 4.6%, placebo = 1.6%). DISCUSSION: Linaclotide significantly reduced multiple abdominal symptoms important to patients with IBS-C (bloating, discomfort, and pain) compared with placebo, as measured by a novel multi-item AS. The AS, derived from the Diary for IBS Symptoms-Constipation, should be considered for use in future IBS-C clinical studies to measure clinically meaningful improvements beyond traditional end points.
引用
- Chang L, Lacy BE, Moshiree B, et al. Efficacy of Linaclotide in Reducing Abdominal Symptoms of Bloating, Discomfort, and Pain: A Phase 3B Trial Using a Novel Abdominal Scoring System. Am J Gastroenterol. 2021. PMID: 34465695. doi:10.14309/ajg.0000000000001334
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。